FDG for therapy of metabolically active tumors

Seminars in Nuclear Medicine

Volumn 42, Issue 3, 2012, Pages 185-189

  Jaini, Sridivya ^a   Dadachova, Ekaterina ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL; BRAIN TOXICITY; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER RADIOTHERAPY; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; ELECTRON; ENDOTHELIUM CELL; FEMALE; HALF LIFE TIME; HUMAN; IN VITRO STUDY; LEUKEMIA; MELANOMA; METASTASIS; MOUSE; NONHUMAN; NUTRIENT; POPULATION ABUNDANCE; POSITRON; POSITRON EMISSION TOMOGRAPHY; SAFETY;

EID: 84859342075     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.12.001     Document Type: Review

References (17)

1. E.M. Rohren, T.G. Turkington, R.E. Coleman Clinical applications of PET in oncology Radiology 231 2004 305 312
2. M.A. Meyer, C.G. Caday, Y. Han Potential radiotherapy of human gliomas with 18F-fluorodeoxyglucose (18F-FDG) Soc Neurosci Abstr 22 1996 948 (abstract)
3. H.P. Stoll, G.D. Hutchins, W.L. Winkle Advantages of short-lived positron-emitting radio-isotopes for intracoronary radiation therapy with liquid-filled balloons to prevent restenosis J Nucl Med 42 2001 1375 1383
4. R.M. Moadel, A.V. Nguyen, E.Y. Lin Positron emission tomography agent 18 F-2-deoxy-2-fluoro-d-glucose (18F-FDG) has a therapeutic potential in breast cancer Breast Cancer Res 5 2003 199 205
5. 18 F-2-deoxy-2-fluoro-d-glucose (18F-FDG) Cancer Res 65 2005 698 702
6. V. Caridad, M. Arsenak, M.J. Abad Effective radiotherapy of primary tumors and metastasis with 18F-2-deoxy-2-fluoro-d-glucose in C57BL/6 mice Cancer Biother Radiopharm 23 2008 371 375
7. 18 F]-labeled 2-deoxy-2-fluoro-d-glucose in a colon cancer mouse model Cancer Biother Radiopharm 25 2010 733 740
8. J.Y. Paik, J.W. Park, K.H. Jung et al. High-dose FDG with combined with nitric oxide stimulation promotes apoptosis and radiation therapy of endothelial cells Nucl Med Biol 2011 Nov 11 [Epub ahead of print]
9. B. Emami, J. Lyman, A. Brown Tolerance of normal tissue to therapeutic irradiation Int J Radiat Oncol Biol Phys 21 1991 109 122
10. S.F. Barrington, M.N. Maisey Skeletal muscle uptake of fluorine-18-FDG: Effect of oral diazepam J Nucl Med 37 1996 1127 1129
11. R.A. Patchell, P.A. Tibbs, W.F. Regine Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial JAMA 280 1998 1485 1489
12. J.K. Moran, H.B. Lee, M.D. Blaufox Optimization of urinary FDG excretion during PET imaging J Nucl Med 40 1999 1352 1357
13. C.J. Edmonds, T. Smith The long-term hazards of the treatment of thyroid cancer with radioiodine Br J Radiol 59 1986 45 51
14. J.G. Rajendran, J.F. Eary, W. Bensinger High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: Pharmacokinetics, biodistribution, and absorbed dose estimation J Nucl Med 43 2002 1383 1390
15. J.E. Mortimer, M.E. Taylor Positron-emitting 18F-2-deoxy-2-fluoro-d- glucose: Potential "hot" new therapy Breast Cancer Res 5 2003 329 331
16. S. Vallabhajosula, L. Solnes, B. Vallabhajosula A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: What is new? Semin Nucl Med 41 2011 246 264
17. S.L. Rice, C.A. Roney, P. Daumar The next generation of positron emission tomography radiopharmaceuticals in oncology Semin Nucl Med 41 2011 265 282